CLINICAL
Family medicine and internal medicine now account for the majority of new starts, claims data show.
Prescribing of GLP-1 receptor agonists by non-endocrinology providers rose 22% over the past year, with family medicine and internal medicine now accounting for the majority of new starts, according to claims data analyzed by IQVIA and reviewed by Scrubswire.
The shift reflects both expanded FDA labels and growing comfort with the drug class outside of specialty clinics.
More from the wire
CLINICAL
A two-year study finds that simplifying the order set, not adding alerts, drove the change.
CLINICAL
The drug, a Nav1.8 inhibitor, is the first new mechanism approved for acute pain in two decades.
CLINICAL
An internal evaluation found visit notes shrunk by 38% with no measurable change in clinical accuracy.
The Morning Round
A free daily email for clinicians, distilled at 6 a.m. ET. One short note. Unsubscribe in one click.
Comments
Be the first to comment.
Thanks — your comment is in the queue. An editor reviews comments before they appear. If yours is on point, you'll see it here within a few hours.